Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORIÂ® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)